Claims for Patent: 6,429,210

Summary for Patent: 6,429,210

Title:	Polymorphic clopidogrel hydrogenesulphate form
Abstract:	Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-.alpha.-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5 -acetate and a process for its preparation.
Inventor(s):	Bousquet; Andre (Sisteron, FR), Castro; Bertrand (Kremlin-Bicetre, FR), Saint-Germain; Jean (Sisteron, FR)
Assignee:	Sanofi-Synthelabo (Paris, FR)
Application Number:	09/623,333
Patent Claims:	1. A crystalline polymorph of (+)-(S) clopidogrel hydrogen sulfate (Form 2), the X ray powder diffractogram of which shows characteristic peaks expressed as interplanar distance at approximately 4.11; 6.86; 3.60; 5.01; 3.74; 6.49 and 5.66 .ANG.. 2. A crystalline polymorph of (+)-(S) clopidogrel hydrogen sulfate (Form 2), the infrared spectrum of which exhibits characteristic absorptions expressed in cm.sup.-1 at 2551, 1497, 1189 and 1029, with respective transmittance percentages of approximately 43; 63.7; 18 and 33.2. 3. A crystalline polymorph of (+)-(S) clopidogrel hydrogen sulfate (Form 2) having a melting point of 176+/-3.degree. C. 4. A crystalline polymorph of clopidogrel hydrogen sulfate (Form 2) exhibiting the X ray powder diffractogram of FIG. 2. 5. A crystalline polymorph of clopidogrel hydrogen sulfate (Form 2) exhibiting the infrared spectrum of FIG. 3. 6. A crystalline polymorph of clopidogrel hydrogen sulfate (Form 2) exhibiting the X ray powder diffractogram which shows characteristic peaks expressed as interplanar distance at approximately 4.11; 6.86; 3.60; 5.01; 3.74; 6.49 and 5.66 .ANG. and an infrared spectrum which shows characteristic absorptions expressed in cm.sup.-1 at 2551, 1497, 1189 and 1029, with respective transmittance percentages of approximately 43, 63.7, 18 and 33.2. 7. A pharmaceutical composition comprising an effective amount of the polymorph Form 2 of clopidogrel hydrogen sulfate according to claim 1 in combination with at least one pharmaceutical excipient. 8. (+)-(S) Clopidogrel hydrogen sulfate, the x-ray powder diffraction pattern of which shows a characteristic peak, expressed in terms of interplanar distance, at approximately 4.11 .ANG.. 9. (+)-(S) Clopidogrel hydrogen sulfate, the x-ray powder diffraction pattern of which shows a characteristic peak, expressed in terms of interplanar distance, at approximately 6.86 .ANG.. 10. (+)-(S) Clopidogrel hydrogen sulfate, the x-ray powder diffraction pattern of which shows a characteristic peak, expressed in terms of interplanar distance, at approximately 3.60 .ANG.. 11. (+)-(S) Clopidogrel hydrogen sulfate, the x-ray powder diffraction pattern of which shows a characteristic peak, expressed in terms of interplanar distance, at approximately 3.87 .ANG.. 12. (+)-(S) Clopidogrel hydrogen sulfate according to claim 8 wherein the x-ray powder diffraction pattern further shows a characteristic peak at approximately 6.86 .ANG.. 13. (+)-(S) Clopidogrel hydrogen sulfate according to claim 12 wherein the x-ray powder diffraction pattern further shows a characteristic peak at approximately 3.60 .ANG.. 14. (+)-(S) Clopidogrel hydrogen sulfate according to claim 9 wherein the x-ray powder diffraction pattern further shows a characteristic peak at approximately 3.60 .ANG.. 15. (+)-(S) Clopidogrel hydrogen sulfate having an enthalpy of fusion of 87 J/g.